Primary liver cancer
Conditions
Interventions
Experimental group :DEB-TACE
control group :CTACE
Sponsors
Shandong Institute of Cancer Prevention and Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years, gender is not limited; 2. Histopathological or clinical diagnosis of primary liver cancer, including hepatocellular carcinoma, cholangiocarcinoma and mixed liver cancer. (Refer to the Specifications for the diagnosis and treatment of primary liver cancer (2011 edition) issued by the Ministry of Health of China); 3. The expected survival period is greater than 3 months; 4. Patients who are unable to cure or require declining treatment for various reasons; 5. Liver function Child-Pugh grade A or B; 6. White blood cell count >= 3.0 x 10^9 / L, hemoglobin >= 8.5g / dl, platelet count >= 50 x10^9 / L; 7. INR <= 2.3 or PT extended <= 3 seconds, serum creatinine < 1.5 times the upper limit of normal; 7. ECOG fitness status score <= 2 points; 8. Patients voluntarily join the study and sign an informed consent form (ICF); 9. Those who are expected to have good compliance can follow up the efficacy and adverse reactions according to the program requirements.
Exclusion criteria
Exclusion criteria: 1. There are obvious venous/intravenous fistulas; uncorrectable coagulopathy and obvious blood abnormalities, with obvious bleeding tendency; refractory massive ascites; 2. Combine active infections, especially biliary system inflammation; 3. Serious heart, lung, kidney, and brain and other important organ diseases; 4. Those who have suffered or are currently concurrent with other malignancies (except for cured basal or squamous cell skin cancer); 5. Events of arteriovenous thrombosis occurring within 12 months prior to screening, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; 6. Uncontrolled infections appear during screening; 7. Pregnant or lactating women; 8. Other patients considered by the treating physician to be unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactJinlong Song
Shandong Institute of Cancer Prevention and Treatment
Outcome results
None listed